ABSTRACT
Background The current study examined the sensitivity of two memory subtests and their corresponding learning slope metrics derived from the African Neuropsychology Battery (ANB) to detect amyloid pathology and APOEε4 status in adults from Kinshasa, the Democratic Republic of the Congo.
Methods 85 participants were classified for the presence of β-amyloid pathology and based on allelic presence of APOEε4. All participants were screened using CSID and AQ, underwent verbal and visuospatial memory testing from ANB, and provided blood samples for plasma Aβ42, Aβ40, and APOE proteotype. Pearson correlation, linear and logistic regression were conducted to compare amyloid pathology and APOEε4 status with derived learning scores, including initial learning, raw learning score, learning over trials, and learning ratio.
Results Our sample included 35 amyloid positive and 44 amyloid negative individuals as well as 42 without and 39 with APOEε4. All ROC AUC ranges for the prediction of amyloid pathology based on learning scores were low, ranging between 0.56-0.70 (95% CI ranging from 0.44-0.82). The sensitivity of all the scores ranged between 54.3-88.6, with some learning metrics demonstrating good sensitivity. Regarding APOEε4 prediction, all AUC values ranged between 0.60-0.69, with all sensitivity measures ranging between 53.8-89.7. There were minimal differences in the AUC values across learning slope metrics, largely due to the lack of ceiling effects in this sample.
Discussion This study demonstrates that some ANB memory subtests and learning slope metrics can discriminate those that are normal from those with amyloid pathology and those with and without APOEε4, consistent with findings reported in Western populations.
Competing Interest Statement
KEY is employed by and receives equity compensation from C2N Diagnostics, LLC. All other authors have no conflict of interest to report.
Funding Statement
This study was supported by grants AARG-19-61778701 and P30AG066511-02S1 from the National Institute on Aging. Dr. Alonso was supported by NIH/NHLBI grant K24HL148521 and NIH/NIA grant P30AG066511. C2N Diagnostics analyses were supported by the NIH (grant No. R44 AG059489), BrightFocus (grant No. CA2016636), The Gerald and Henrietta Rauenhorst Foundation, and the Alzheimers Drug Discovery Foundation (grant No. GC-201711-2013978).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was approved by the Ethics Committee and Institutional Review Boards of the University of Kinshasa.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
This version of the manuscript has been revised to update Table 3's sensitivity/specificity values, as they were flipped to accurately reflect the sensitivity/specificity of the cognitive tests predicting amyloid and APOE status.
Data Availability
The data supporting the findings of this study are available on request from the corresponding author. The data are not publicly available due to privacy or ethical reasons.
